CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
76 hedge funds and large institutions have $63.7M invested in CTI BioPharma Corp. (DE) Common Stock in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 13 reducing their positions, and 9 closing their positions.
123% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 13
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
23% more capital invested
Capital invested by funds: $52M → $63.7M (+$11.8M)
13% more funds holding
Funds holding: 67 → 76 (+9)
90% less call options, than puts
Call options by funds: $747K | Put options by funds: $7.58M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.12M |
| 2 |
Goldman Sachs
New York
|
+$1.5M |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$932K |
| 4 |
State Street
Boston,
Massachusetts
|
+$864K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$603K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$5.97M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$465K |
| 3 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$327K |
| 4 |
Morgan Stanley
New York
|
-$321K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$192K |
CTIC Hedge Fund Activity: Q4 2013 in Review
76 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2013, worth a combined $63.7M — up 23% from $52M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CTIC positions and 9 closed out — a net gain of 9 holders — while 29 added to existing stakes and 13 trimmed.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $3.12M. The largest seller was Perceptive Advisors, cutting an estimated $5.97M.
- 76 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2013, up from 67 in Q3 2013.
- Funds reported $63.7M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2013, up 23% quarter-over-quarter.
- 18 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2013 and 9 closed out, a net change of +9 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2013 was Oxford Asset Management, an estimated $3.12M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2013 was Perceptive Advisors, an estimated $5.97M sold.
Based on aggregated 13F filings for Q4 2013.